Natural History in Children Up to 16 Years with Mild to Profound Hearing Loss Due to Mutations in GJB2 / OTOF Genes

Last updated: February 12, 2025
Sponsor: Sensorion
Overall Status: Active - Recruiting

Phase

N/A

Condition

Hearing Impairment

Hearing Loss

Deafness

Treatment

Pure Tone Audiometry Assessment

Quality of Life Questionnaires

Clinical Study ID

NCT05402813
SENS-NH01
  • Ages < 16
  • All Genders

Study Summary

The purpose of this study is to follow the natural history of non-syndromic hearing loss caused by mutations in two genes (GJB2 or OTOF) in children up to 16 years of age.

Eligibility Criteria

Inclusion

Main Inclusion Criteria:

Participants meeting all the following main inclusion criteria will be eligible to participate in the study:

  • Aged ≤ 16 years on the date of signed informed consent for cohort 1 and ≤ 10 yearsfor cohort 2;

  • With a diagnosis of non-syndromic, bilateral, mild to profound, sensorineuralhearing loss (according to the American Speech Language-Hearing Association);

  • With documented genotyping results showing mutation(s) in GJB2 or OTOF genes;

  • Written informed consent as required by local regulations.

  • Either without Cochlear Implant, or with unilateral or bilateral Cochlear Implant(s)

Exclusion

Exclusion Criteria:

Participants presenting with any of the following main exclusion criteria will not be included in the study

  • Other type of deafness, such as unilateral deafness, persistent conductive deafness,malformation syndrome, syndromic deafness, known familial deafness linked tomutations in other genes than OTOF or GJB2;

  • Documented genotyping results showing pathogenic mutation(s) in other gene(s) thanGJB2 or OTOF genes in the tested panel;

  • Unable and/or unwilling to comply with all the protocol requirements and/or studyprocedures.

Study Design

Total Participants: 180
Treatment Group(s): 2
Primary Treatment: Pure Tone Audiometry Assessment
Phase:
Study Start date:
November 18, 2022
Estimated Completion Date:
November 18, 2028

Study Description

The study aims to:

  • better describe the prevalence of cases of DFNB1A and DFNB9, including the type of mutations, and to assess the clinical course of the disease in children up to 16 years of age who have a mild to profound deafness.

  • better understand the audiological and genetic characteristics of the participants with congenital versus evolutive DFNB1A and DFNB9 deafness.

Connect with a study center

  • Necker Hospital

    Paris,
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.